EBEmma Bohn

Emma Bohn

*This is an algorithmically generated author record based on publicly available information.

Emma Bohn has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DeepRNAi: Predicting on- and off-target siRNA activity and establishing a benchmark

    by Nicolas Y. Masse, Tammy T.Y. Lau, Jeff Wintersinger, Mykhaylo Slobodyanyuk, Roujia Li, Vivian S. Chu, Helen Zhu, Bhargav Kanuparthi, Jonathan La, Brodie Fischbacher, et al.

    Small interfering RNAs (siRNAs) silence target genes through RISC-mediated hybridization and cleavage, but can silence unintended transcripts and cause toxicity or complicate regulatory approval. In drug development, empirical assessment by qPCR and RNA-seq is slow, forces early candidate prioritization, and is limited by available species- and genome-appropriate cell models. While extensive empirical screening remains standard practice, there is a significant opportunity for modern AI methods to change this paradigm. We introduce DeepRNAi, a deep learning model that accurately predicts on- and off-target knockdown from siRNA and mRNA sequence. Trained on 16 million siRNA-transcript pairs from 2,031 siRNAs designed to interrogate known siRNA failure modes, and incorporating transcript context from biological foundation models, DeepRNAi is the first in silico method that approaches experimental accuracy. It generalizes across cell models, transcripts, genomes and species, and in a small study distinguishes approved therapeutics from hepatotoxic candidates. The value of DeepRNAi for prioritizing better candidates up front improving likelihood of success later in development is evidenced by a genome-wide survey of 24.4 million siRNAs targeting 7,946 genes, which indicates that 90.1% of the 100 most potent siRNAs have at least some off-target concerns. To support the community, we are publishing a training and benchmark dataset containing 1.84 million siRNA-transcript pairs from 240 siRNAs.

  • Open Access

    Three‐year outcomes of repeated botulinum neurotoxin A injections to the lower extremities in young children with spastic cerebral palsy in GMFCS levels I to III

    by Darcy Fehlings, Emma Bohn, Lauren Switzer, Charles H Goldsmith, Unni Narayanan, Peter L Rosenbaum, F Virginia Wright, Gary Foster, CP‐BoNT‐A Study Group

    Aim: To evaluate the effectiveness of repeated botulinum neurotoxin A (BoNT‐A) injections on gross motor function over 3 years in ambulant children with spastic cerebral palsy (CP). Method: A prospective observational cohort study of 124 participants was conducted comparing outcomes in children (aged 2–6 years) with spastic CP functioning in Gross Motor Function Classification System (GMFCS) levels I to III who did and did not receive BoNT‐A. The primary outcome was the 66‐item Gross Motor Function Measure (GMFM‐66), assessed at baseline and annually over 3 years. Secondary outcomes included passive ankle dorsiflexion with knee extended (PADKE) and several measures of activity and participation. Results: A total of 117 participants (94%), consisting of 61 cases and 56 comparisons, were assessed on the GMFM‐66 at a follow‐up of 1 year or longer, with 106 (85%) assessed at year 3. There were no significant differences in mean GMFM‐66 scores adjusted for baseline differences between groups over time ( β̂ group = 0.92, standard error [SE] = 0.81, 95% confidence interval [CI] = − 0.66 to 2.50; p = 0.256). A difference in PADKE favouring the comparison group was observed ( β̂ group = − 4.17, SE = 1.58, 95% CI = − 7.27 to − 1.08; p = 0.009), approaching the 5° minimally important difference. Interpretation: Repeated BoNT‐A injections over 3 years were not associated with improvements in gross motor function or passive ankle dorsiflexion range in young children with spastic CP functioning in GMFCS levels I to III compared to a comparison group not receiving BoNT‐A.


  • Open Access

    Sequence based prediction of cell type specific microRNA binding and mRNA degradation for therapeutic discovery

    by Bhargav Kanuparthi, Sara E. Pour, Scott D. Findlay, Omar Wagih, Jahir M. Gutierrez, Rory Gao, Jeff Wintersinger, Junru Lin, Martino Gabra, Emma Bohn, et al.

    MicroRNAs and RNA binding proteins are crucial elements of post-transcriptional gene regulation, which governs the fate of mRNA molecules in the cell. However, the landscape of these regulatory interactions, particularly across different mammalian cell types, remains underexplored. We describe REPRESS, a deep learning model that predicts cell-type-specific microRNA binding and mRNA degradation directly from RNA sequence. REPRESS was trained on AGO2-CLIP, miR-eCLIP and Degradome-Seq data profiling millions of microRNA binding and mRNA degradation sites across multiple cell types in human and mouse. It reveals biology that other state-of-the-art methods did not, such as identifying repressive non-canonical miRNA target sites and decoding the regulatory effects of sequence context and miRNA binding site multiplicity. REPRESS outperforms other advanced methods and neural architectures on a comprehensive suite of seven orthogonal tasks, including identifying genetic variants that affect microRNA binding, predicting out-of-distribution data from massively parallel reporter assays, and predicting canonical and non-canonical miRNA mediated repression. To demonstrate the general utility of REPRESS, we show that it provides insights into novel biology and the design of RNA therapeutics. Code is available at : https://github.com/deepgenomics/repress


  • Open Access

    Pharmacological and neurosurgical management of cerebral palsy and dystonia: Clinical practice guideline update

    by Darcy Fehlings, Brenda Agnew, Hortensia Gimeno, Adrienne Harvey, Kate Himmelmann, Jean‐Pierre Lin, Jonathan W. Mink, Elegast Monbaliu, James Rice, Emma Bohn, et al.

    Dystonia, typically characterized by slow repetitive involuntary movements, stiff abnormal postures, and hypertonia, is common among individuals with cerebral palsy (CP). Dystonia can interfere with activities and have considerable impact on motor function, pain/comfort, and ease of caregiving. Although pharmacological and neurosurgical approaches are used clinically in individuals with CP and dystonia that is causing interference, evidence to support these options is limited. This clinical practice guideline update comprises 10 evidence‐based recommendations on the use of pharmacological and neurosurgical interventions for individuals with CP and dystonia causing interference, developed by an international expert panel following the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. The recommendations are intended to help inform clinicians in their use of these management options for individuals with CP and dystonia, and to guide a shared decision‐making process in selecting a management approach that is aligned with the individual's and the family's values and preferences.


  • Top Cited Papers
    Open Access

    Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta‐analysis

    by Emma Bohn, Katherine Goren, Lauren Switzer, Yngve Falck‐Ytter, Darcy Fehlings

    Aim: To update a systematic review of evidence published up to December 2015 for pharmacological/neurosurgical interventions among individuals with cerebral palsy (CP) and dystonia.Method: Searches were updated (January 2016 to May 2020) for oral baclofen, trihexyphenidyl, benzodiazepines, clonidine, gabapentin, levodopa, botulinum neurotoxin (BoNT), intrathecal baclofen (ITB), and deep brain stimulation (DBS), and from database inception for medical cannabis. Eligible studies included at least five individuals with CP and dystonia and reported on dystonia, goal achievement, motor function, pain/comfort, ease of caregiving, quality of life (QoL), or adverse events. Evidence certainty was evaluated using GRADE.Results: Nineteen new studies met inclusion criteria (two trihexyphenidyl, one clonidine, two BoNT, nine ITB, six DBS), giving a total of 46 studies (four randomized, 42 non‐randomized) comprising 915 participants when combined with those from the original systematic review. Very low certainty evidence supported improved dystonia (clonidine, ITB, DBS) and goal achievement (clonidine, BoNT, ITB, DBS). Low to very low certainty evidence supported improved motor function (DBS), pain/comfort (clonidine, BoNT, ITB, DBS), ease of caregiving (clonidine, BoNT, ITB), and QoL (ITB, DBS). Trihexyphenidyl, clonidine, BoNT, ITB, and DBS may increase adverse events. No studies were identified for benzodiazepines, gabapentin, oral baclofen, and medical cannabis.Interpretation: Evidence evaluating the use of pharmacological and neurosurgical management options for individuals with CP and dystonia is limited to between low and very low certainty. What this paper adds: Meta‐analysis suggests that intrathecal baclofen (ITB) and deep brain stimulation (DBS) may improve dystonia and pain. Meta‐analysis suggests that DBS may improve motor function. Clonidine, botulinum neurotoxin, ITB, and DBS may improve achievement of individualized goals. ITB and DBS may improve quality of life. No direct evidence is available for oral baclofen, benzodiazepines, gabapentin, or medical cannabis.